DOI: http://dx.doi.org/10.18203/2349-2902.isj20184654

Study of ER PR receptors in breast carcinoma: a study of 30 cases

Himanshu R. Patel, Ankur Shrimal, Harsh P. Trivedi

Abstract


Background: Estrogen and Progesterone receptors are found in breast cancer cells that depend on estrogen and related hormones to grow. These are steroidal nuclear type of receptors. The most common method currently used to test a tumor for estrogen and progesterone receptors is immunohistochemistry or IHC. Patients with positive hormone receptor cancer have better survival. They are candidates of anti-hormonal therapy.

Methods: This is a retrospective study was carried out in the Department of Surgery of a tertiary care hospital, affiliated to Government Medical College. This is a retrospective study in which 30 randomly selected case records of breast cancer patients, who presented in the period between 2011 to 2016, and who had undergone surgery, were taken and studied in terms of history, examination, investigations, treatment given, histopathology report and development of recurrence, metastasis and survival.

Results: In this study out of 30 patients, 25 patients received adjuvant chemotherapy. 2 patients developed recurrence at local site.1 patient was ER/PR both negative and 1 patient was ER +/PR-. 3 patients developed metastasis. Among these, 2 patients were ER/PR both negative and 1 patient was having ER/PR both positive.

Conclusions: Hormone receptors play a significant role in breast carcinoma. Breast cancer is more common in postmenopausal group as compared to premenopausal group. Mean age at diagnosis of breast cancer in western countries is 61 years and in India it is 50 years.


Keywords


Carcinoma breast, Estrogen receptor, Progesterone receptor

Full Text:

PDF

References


Hunt KK, Robertson JFR, Bland KI. The Breast. In: Brunicardi FC, Anderson DK, Billiar TR, Dunn DL, Hunter JG, Matthews JB, Pollock RE, eds. Schwartz’s Principles of Surgery. 10th Edition McGraw-Hill Education; 2015;17:467-564.

Breastcancer. Hormone receptor status. Available at https://www.breastcancer.org/symptoms/diagnosis/hormone_status

Sainsbury R. Breast. In: Williams NS, Christopher JK, Bulstrode P. Ronan O’Connell. Bailey and Love’s short practice of surgery. 25th edition Edward Arnold (Publishers) Ltd; 2008;50:827-850.

Consensus Document for management of breast cancer. ICMR. 2016.

Sofi GN. Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement. Asian Pacific J Cancer Prev. 2012;13(10):5047-52.

Lester SC. Breast. In: Kumar V, Abbas AK, Fausto N, Aster JC. Robbins and cotran pathologic basis of disease. 8th edition. Saunders, an imprint of Elsevier Inc; 2010;23:2058-78.

Leong SPL, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik N, et al. Is breast cancer the same disease in Asian and western countries? World J Surg. 2010;34:2308-24.

Richard Sainsbury, breast,InNorman S. Williams Christopher J.K. Bulstrode P. Ronan O’Connell Bailey & Love’s short practice of surgery 25th edition Edward Arnold (Publishers) Ltd; 2008;50:827-50.

Alsaeed EF. Elevated preoperative serum cancer antigen 15.3 levels are associated with reduced disease-free survival: a single- institution experience. Dove Press Journal Breast Cancer- Targets Therapy. 2013;2013(5):53-9.

Al Azawi D. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer. 2006;6:220.

Kopans DB. Diagnostic breast imaging: textbook of breast cancer. 3rd edition. LWW; 2006;9:116-20.

Gion' M. The tumour associated antigen CA15.3 in primary breast cancer. Br J Cancer. 1991;63:809-13.

Dutta V. Chopra GS, Sahai K, Nema SK. Hormone rectors, HER -/ neu and chromosomal aberrations in breast cancer. MJAFI; 2008;64:11-5.

Vasdha BM, Bharti JM, Prashant PM. Correlation of hormone receptor and HER-2/neu expression in breast cancer. A study at tertiary care centre in south Gujarat. Nat J Med Res. 2012;2:295-8.

Azizun-Nisa, Bhurgri Y, Raza F, Kayani N. Comparison of ER, PR and HER- 2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pac J Cancer Prev. 2008;9:553-6.

Sharma S. A dissertation on evaluation of breast cancer with histologicalgrading along with estrogen receptors, progesterone receptors and HER-2/neu status, Department of pathology, Shri M.P.Shah Medical college, Jamnagar. 2014.

Sofi GN. Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement. Asian Pacific J Cancer Prev. 2012;13(10):5047-52.

Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol. 2005;123:541-6.

Shet T, Agrawal A, Nadkarni M. Hormone receptors over the last 8 years in a cancer referral center in India: what was and what is? Indian J Pathol Microbiol. 2009;52:171.

AllemaniC, Weir HK, Helena. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). The Lancet. 2015;385(9972):977-1010.

Naeem M, Nasir A, Aman Z, Ahmad T, Samad A. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer. J Ayub Med Coll Abbottabad. 2008;20(3).

Patey DH, Dyson WH. The prognosis of carcinoma of the breast in relation to the type of operation performed. Br J Cancer. 1948;2:7-13.

Khemka A. Palpable breast lumps: incisional biopsy versus Histopathology: a correlation of diagnostic accuracy. Internet J Surg. 2009;18(1).